Selection of novel analogs of thalidomide with enhanced tumor necrosis factor α inhibitory activity

Molecular Medicine

Volumn 2, Issue 4, 1996, Pages 506-515

  Corral, Laura G ^a   Muller, George W ^a   Moreira, André L ^b   Chen, Yuxi ^a   Wu, Mingdan ^a   Stirling, David ^a   Kaplan, Gilla ^b  

^a CELGENE CORPORATION   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CC 1069; CC 1104; CC 1115; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYBRIDIZATION; INFLAMMATION; MONOCYTE; NORTHERN BLOTTING; PRIORITY JOURNAL;

EID: 0029742896     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401909     Document Type: Article

References (21)

1. Mellin GW, Katzenstein. (1994) The saga of thalidomide: Neuropathy to embriopathy, with case reports and congenial anomalies. N. Engl. J. Med. 267: 1184-1244.
2. Sampaio EP, Sarno EN, Gallily R, Cohn ZA, Kaplan G. (1991) Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J. Exp. Med. 173: 699-703.
3. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. (1993) Thalidomide exerts its inhibition action on tumor necrosis factor α by enhancing mRNA degradation. J. Exp. Med. 177: 1675-1680.
4. Sampaio EP, Kaplan G, Miranda A, et al. (1993) The influence of thalidomide on the clinical and immunological manifestation of erythema nodosum leprosum. J. Infect. Dis. 168: 408-414.
5. Tramontana JM, Utaipat U, Molloy A, et al. (1995) Thalidomide treatment reduces fumor necrosis factor-α production and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med. 1: 384-397.
6. Schumacher H, Smith RL, Williams RT. (1965) The metabolism of thalidomide: The spontaneous hydrolysis of thalidomide in solution. Br. J. Pharmacol. 25: 324.
7. Georgopoulos A, Koch HP, Czejka MJ. (1990) In-vitro kinetics and metabolism of a phthalimido-glutarimide. Int. J. Exp. Clin. Chemotherapy 3: 135-141.
8. Silva AT, Bayston KF, Cohen J. (1990) Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-α in experimental gram-negative shock. J. Infect. Dis. 162: 421-427.
9. Tracey KJ, Pong Y, Hesse DG, et al. (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330: 662-664.
10. Muller G, Corral L, Shire M, Kaplan G, Stirling D. (1995) Novel inhibitors of tumor necrosis factor-α. Presented at the 210th American Chemical Society Meeting, Chicago, IL. Abstract 84.
11. Eriksson T, Bjorkman S, Fyge A. (1992) Determination of thalidomide in plasma and blood by high-performance liquid chromatography: Avoiding hydrolytic degradation. J. Chromatography 582: 211-216.
12. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, Vries JE. (1991) Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174: 1209-1220.
13. Fong Y, Tracey KJ, Moldawer LL, et al. (1989) A. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J. Exp. Med. 170: 1627-1633.
14. Burroughs MH, Tsenova-Berkova L, Sokol K, Ossig J, Tuomanen E, Kaplan G. (1995) Effect of thalidomide on the inflammatory response in cerebrospinal fluid in experimental meningitis. Microb. Pathog. 19: 245-255.
15. Bogdan C, Vodovotz Y, Nathan C. (1991) Macrophage deactivation by interleukin 10. J. Exp. Med. 174: 1549-1555.
16. Tannenbaum CS, Hamilton TA. (1989) Lipopolysaccharide induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J. Immunol 142: 1274-1279.
17. Platzer C, Meisel C, Vogt K, Platzer M, Volk HD. (1994) Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating drugs. Int. Immunol. 7: 517-523.
18. Standiford TJ, Strieter RM, Lukacs NW, Kunkel L. (1995) Neutralization of IL-10 increases lethality in endotoxemia. J. Immunol. 155: 2222-2229.
19. van der Poll T, Marchant A, Buurman WA, et al. (1995) Endogenous IL-10 protects mice from death during septic peritonitis. J. Immunol. 155: 5397-5401.
20. Koch HP. (1985) Thalidomide and congeners as anti-inflammatory agents. In: Ellis GP, West GB (eds). Progress in Medicinal Chemistry. Vol. 22 Elseviers Science Publishers, Amsterdam, pp. 165-242.
21. D'Amato JR, Loughman MS, Flynn E, Folkman J. (1994) Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 91: 4982-4985.